

Global Long-acting PrEP Market Growth 2026-2032

<https://marketpublishers.com/r/L5110371D72BEN.html>

Date: January 2026

Pages: 81

Price: US\$ 3,660.00 (Single User License)

ID: L5110371D72BEN

Abstracts

The global Long-acting PrEP market size is predicted to grow from US\$ 305 million in 2025 to US\$ 834 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.

Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop-start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers,

elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services. In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers' gross margins ranged between 60% and 70%.

The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery: reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.

Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations: risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother start/pause/restart pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.

Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug

?tail,? injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity?aseptic manufacturing, cold-chain logistics, and reliable component availability?adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.

LP Information, Inc. (LPI) ' newest research report, the ?Long-acting PrEP Industry Forecast? looks at past sales and reviews total world Long-acting PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-acting PrEP sales for 2026 through 2032. With Long-acting PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Long-acting PrEP industry.

This Insight Report provides a comprehensive analysis of the global Long-acting PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-acting PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Long-acting PrEP market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-acting PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-acting PrEP.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-acting PrEP market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Cabotegravir

Lenacapavir

Other

Segmentation by Dosing Interval:

Short-interval Injections

Monthly Injections

Quarterly Injections

Segmentation by Drug Properties:

Original Drug

Generic Drug

Segmentation by Application:

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Gilead Sciences

ViiV Healthcare

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-acting PrEP market?

What factors are driving Long-acting PrEP market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-acting PrEP market opportunities vary by end market size?

How does Long-acting PrEP break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Long-acting PrEP Annual Sales 2021-2032

- 2.1.2 World Current & Future Analysis for Long-acting PrEP by Geographic Region, 2021, 2025 & 2032

- 2.1.3 World Current & Future Analysis for Long-acting PrEP by Country/Region, 2021, 2025 & 2032

2.2 Long-acting PrEP Segment by Type

- 2.2.1 Cabotegravir

- 2.2.2 Lenacapavir

- 2.2.3 Other

- 2.2.4 Long-acting PrEP Sales by Type

- 2.2.4.1 Global Long-acting PrEP Sales Market Share by Type (2021-2026)

- 2.2.4.2 Global Long-acting PrEP Revenue and Market Share by Type (2021-2026)

- 2.2.4.3 Global Long-acting PrEP Sale Price by Type (2021-2026)

2.3 Long-acting PrEP Segment by Dosing Interval

- 2.3.1 Short-interval Injections

- 2.3.2 Monthly Injections

- 2.3.3 Quarterly Injections

- 2.3.4 Long-acting PrEP Sales by Dosing Interval

- 2.3.4.1 Global Long-acting PrEP Sales Market Share by Dosing Interval (2021-2026)

- 2.3.4.2 Global Long-acting PrEP Revenue and Market Share by Dosing Interval (2021-2026)

- 2.3.4.3 Global Long-acting PrEP Sale Price by Dosing Interval (2021-2026)

2.4 Long-acting PrEP Segment by Drug Properties

2.4.1 Original Drug

2.4.2 Generic Drug

2.4.3 Long-acting PrEP Sales by Drug Properties

2.4.3.1 Global Long-acting PrEP Sales Market Share by Drug Properties (2021-2026)

2.4.3.2 Global Long-acting PrEP Revenue and Market Share by Drug Properties (2021-2026)

2.4.3.3 Global Long-acting PrEP Sale Price by Drug Properties (2021-2026)

2.5 Long-acting PrEP Segment by Application

2.5.1 Hospital

2.5.2 Clinic

2.5.3 Other

2.5.4 Long-acting PrEP Sales by Application

2.5.4.1 Global Long-acting PrEP Sale Market Share by Application (2021-2026)

2.5.4.2 Global Long-acting PrEP Revenue and Market Share by Application (2021-2026)

2.5.4.3 Global Long-acting PrEP Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Long-acting PrEP Breakdown Data by Company

3.1.1 Global Long-acting PrEP Annual Sales by Company (2021-2026)

3.1.2 Global Long-acting PrEP Sales Market Share by Company (2021-2026)

3.2 Global Long-acting PrEP Annual Revenue by Company (2021-2026)

3.2.1 Global Long-acting PrEP Revenue by Company (2021-2026)

3.2.2 Global Long-acting PrEP Revenue Market Share by Company (2021-2026)

3.3 Global Long-acting PrEP Sale Price by Company

3.4 Key Manufacturers Long-acting PrEP Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Long-acting PrEP Product Location Distribution

3.4.2 Players Long-acting PrEP Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LONG-ACTING PREP BY GEOGRAPHIC REGION

- 4.1 World Historic Long-acting PrEP Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Long-acting PrEP Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Long-acting PrEP Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Long-acting PrEP Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Long-acting PrEP Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Long-acting PrEP Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Long-acting PrEP Sales Growth
- 4.4 APAC Long-acting PrEP Sales Growth
- 4.5 Europe Long-acting PrEP Sales Growth
- 4.6 Middle East & Africa Long-acting PrEP Sales Growth

5 AMERICAS

- 5.1 Americas Long-acting PrEP Sales by Country
 - 5.1.1 Americas Long-acting PrEP Sales by Country (2021-2026)
 - 5.1.2 Americas Long-acting PrEP Revenue by Country (2021-2026)
- 5.2 Americas Long-acting PrEP Sales by Type (2021-2026)
- 5.3 Americas Long-acting PrEP Sales by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Long-acting PrEP Sales by Region
 - 6.1.1 APAC Long-acting PrEP Sales by Region (2021-2026)
 - 6.1.2 APAC Long-acting PrEP Revenue by Region (2021-2026)
- 6.2 APAC Long-acting PrEP Sales by Type (2021-2026)
- 6.3 APAC Long-acting PrEP Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

7.1 Europe Long-acting PrEP by Country

7.1.1 Europe Long-acting PrEP Sales by Country (2021-2026)

7.1.2 Europe Long-acting PrEP Revenue by Country (2021-2026)

7.2 Europe Long-acting PrEP Sales by Type (2021-2026)

7.3 Europe Long-acting PrEP Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Long-acting PrEP by Country

8.1.1 Middle East & Africa Long-acting PrEP Sales by Country (2021-2026)

8.1.2 Middle East & Africa Long-acting PrEP Revenue by Country (2021-2026)

8.2 Middle East & Africa Long-acting PrEP Sales by Type (2021-2026)

8.3 Middle East & Africa Long-acting PrEP Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Long-acting PrEP

10.3 Manufacturing Process Analysis of Long-acting PrEP

10.4 Industry Chain Structure of Long-acting PrEP

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Long-acting PrEP Distributors

11.3 Long-acting PrEP Customer

12 WORLD FORECAST REVIEW FOR LONG-ACTING PREP BY GEOGRAPHIC REGION

12.1 Global Long-acting PrEP Market Size Forecast by Region

12.1.1 Global Long-acting PrEP Forecast by Region (2027-2032)

12.1.2 Global Long-acting PrEP Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Long-acting PrEP Forecast by Type (2027-2032)

12.7 Global Long-acting PrEP Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Gilead Sciences

13.1.1 Gilead Sciences Company Information

13.1.2 Gilead Sciences Long-acting PrEP Product Portfolios and Specifications

13.1.3 Gilead Sciences Long-acting PrEP Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Gilead Sciences Main Business Overview

13.1.5 Gilead Sciences Latest Developments

13.2 ViiV Healthcare

13.2.1 ViiV Healthcare Company Information

13.2.2 ViiV Healthcare Long-acting PrEP Product Portfolios and Specifications

13.2.3 ViiV Healthcare Long-acting PrEP Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 ViiV Healthcare Main Business Overview

13.2.5 ViiV Healthcare Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Long-acting PrEP Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Long-acting PrEP Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Cabotegravir

Table 4. Major Players of Lenacapavir

Table 5. Major Players of Other

Table 6. Global Long-acting PrEP Sales by Type (2021-2026) & (K Dose)

Table 7. Global Long-acting PrEP Sales Market Share by Type (2021-2026)

Table 8. Global Long-acting PrEP Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Long-acting PrEP Revenue Market Share by Type (2021-2026)

Table 10. Global Long-acting PrEP Sale Price by Type (2021-2026) & (US\$/Dose)

Table 11. Major Players of Short-interval Injections

Table 12. Major Players of Monthly Injections

Table 13. Major Players of Quarterly Injections

Table 14. Global Long-acting PrEP Sales by Dosing Interval (2021-2026) & (K Dose)

Table 15. Global Long-acting PrEP Sales Market Share by Dosing Interval (2021-2026)

Table 16. Global Long-acting PrEP Revenue by Dosing Interval (2021-2026) & (\$ million)

Table 17. Global Long-acting PrEP Revenue Market Share by Dosing Interval (2021-2026)

Table 18. Global Long-acting PrEP Sale Price by Dosing Interval (2021-2026) & (US\$/Dose)

Table 19. Major Players of Original Drug

Table 20. Major Players of Generic Drug

Table 21. Global Long-acting PrEP Sales by Drug Properties (2021-2026) & (K Dose)

Table 22. Global Long-acting PrEP Sales Market Share by Drug Properties (2021-2026)

Table 23. Global Long-acting PrEP Revenue by Drug Properties (2021-2026) & (\$ million)

Table 24. Global Long-acting PrEP Revenue Market Share by Drug Properties (2021-2026)

Table 25. Global Long-acting PrEP Sale Price by Drug Properties (2021-2026) & (US\$/Dose)

Table 26. Global Long-acting PrEP Sale by Application (2021-2026) & (K Dose)

Table 27. Global Long-acting PrEP Sale Market Share by Application (2021-2026)

- Table 28. Global Long-acting PrEP Revenue by Application (2021-2026) & (\$ million)
- Table 29. Global Long-acting PrEP Revenue Market Share by Application (2021-2026)
- Table 30. Global Long-acting PrEP Sale Price by Application (2021-2026) & (US\$/Dose)
- Table 31. Global Long-acting PrEP Sales by Company (2021-2026) & (K Dose)
- Table 32. Global Long-acting PrEP Sales Market Share by Company (2021-2026)
- Table 33. Global Long-acting PrEP Revenue by Company (2021-2026) & (\$ millions)
- Table 34. Global Long-acting PrEP Revenue Market Share by Company (2021-2026)
- Table 35. Global Long-acting PrEP Sale Price by Company (2021-2026) & (US\$/Dose)
- Table 36. Key Manufacturers Long-acting PrEP Producing Area Distribution and Sales Area
- Table 37. Players Long-acting PrEP Products Offered
- Table 38. Long-acting PrEP Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- Table 39. New Products and Potential Entrants
- Table 40. Market M&A Activity & Strategy
- Table 41. Global Long-acting PrEP Sales by Geographic Region (2021-2026) & (K Dose)
- Table 42. Global Long-acting PrEP Sales Market Share Geographic Region (2021-2026)
- Table 43. Global Long-acting PrEP Revenue by Geographic Region (2021-2026) & (\$ millions)
- Table 44. Global Long-acting PrEP Revenue Market Share by Geographic Region (2021-2026)
- Table 45. Global Long-acting PrEP Sales by Country/Region (2021-2026) & (K Dose)
- Table 46. Global Long-acting PrEP Sales Market Share by Country/Region (2021-2026)
- Table 47. Global Long-acting PrEP Revenue by Country/Region (2021-2026) & (\$ millions)
- Table 48. Global Long-acting PrEP Revenue Market Share by Country/Region (2021-2026)
- Table 49. Americas Long-acting PrEP Sales by Country (2021-2026) & (K Dose)
- Table 50. Americas Long-acting PrEP Sales Market Share by Country (2021-2026)
- Table 51. Americas Long-acting PrEP Revenue by Country (2021-2026) & (\$ millions)
- Table 52. Americas Long-acting PrEP Sales by Type (2021-2026) & (K Dose)
- Table 53. Americas Long-acting PrEP Sales by Application (2021-2026) & (K Dose)
- Table 54. APAC Long-acting PrEP Sales by Region (2021-2026) & (K Dose)
- Table 55. APAC Long-acting PrEP Sales Market Share by Region (2021-2026)
- Table 56. APAC Long-acting PrEP Revenue by Region (2021-2026) & (\$ millions)
- Table 57. APAC Long-acting PrEP Sales by Type (2021-2026) & (K Dose)
- Table 58. APAC Long-acting PrEP Sales by Application (2021-2026) & (K Dose)
- Table 59. Europe Long-acting PrEP Sales by Country (2021-2026) & (K Dose)

- Table 60. Europe Long-acting PrEP Revenue by Country (2021-2026) & (\$ millions)
- Table 61. Europe Long-acting PrEP Sales by Type (2021-2026) & (K Dose)
- Table 62. Europe Long-acting PrEP Sales by Application (2021-2026) & (K Dose)
- Table 63. Middle East & Africa Long-acting PrEP Sales by Country (2021-2026) & (K Dose)
- Table 64. Middle East & Africa Long-acting PrEP Revenue Market Share by Country (2021-2026)
- Table 65. Middle East & Africa Long-acting PrEP Sales by Type (2021-2026) & (K Dose)
- Table 66. Middle East & Africa Long-acting PrEP Sales by Application (2021-2026) & (K Dose)
- Table 67. Key Market Drivers & Growth Opportunities of Long-acting PrEP
- Table 68. Key Market Challenges & Risks of Long-acting PrEP
- Table 69. Key Industry Trends of Long-acting PrEP
- Table 70. Long-acting PrEP Raw Material
- Table 71. Key Suppliers of Raw Materials
- Table 72. Long-acting PrEP Distributors List
- Table 73. Long-acting PrEP Customer List
- Table 74. Global Long-acting PrEP Sales Forecast by Region (2027-2032) & (K Dose)
- Table 75. Global Long-acting PrEP Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 76. Americas Long-acting PrEP Sales Forecast by Country (2027-2032) & (K Dose)
- Table 77. Americas Long-acting PrEP Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 78. APAC Long-acting PrEP Sales Forecast by Region (2027-2032) & (K Dose)
- Table 79. APAC Long-acting PrEP Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 80. Europe Long-acting PrEP Sales Forecast by Country (2027-2032) & (K Dose)
- Table 81. Europe Long-acting PrEP Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 82. Middle East & Africa Long-acting PrEP Sales Forecast by Country (2027-2032) & (K Dose)
- Table 83. Middle East & Africa Long-acting PrEP Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 84. Global Long-acting PrEP Sales Forecast by Type (2027-2032) & (K Dose)
- Table 85. Global Long-acting PrEP Revenue Forecast by Type (2027-2032) & (\$ millions)
- Table 86. Global Long-acting PrEP Sales Forecast by Application (2027-2032) & (K

Dose)

Table 87. Global Long-acting PrEP Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 88. Gilead Sciences Basic Information, Long-acting PrEP Manufacturing Base, Sales Area and Its Competitors

Table 89. Gilead Sciences Long-acting PrEP Product Portfolios and Specifications

Table 90. Gilead Sciences Long-acting PrEP Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 91. Gilead Sciences Main Business

Table 92. Gilead Sciences Latest Developments

Table 93. ViiV Healthcare Basic Information, Long-acting PrEP Manufacturing Base, Sales Area and Its Competitors

Table 94. ViiV Healthcare Long-acting PrEP Product Portfolios and Specifications

Table 95. ViiV Healthcare Long-acting PrEP Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 96. ViiV Healthcare Main Business

Table 97. ViiV Healthcare Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Long-acting PrEP
- Figure 2. Long-acting PrEP Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Long-acting PrEP Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global Long-acting PrEP Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Long-acting PrEP Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Long-acting PrEP Sales Market Share by Country/Region (2025)
- Figure 10. Long-acting PrEP Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Cabotegravir
- Figure 12. Product Picture of Lenacapavir
- Figure 13. Product Picture of Other
- Figure 14. Global Long-acting PrEP Sales Market Share by Type in 2026
- Figure 15. Global Long-acting PrEP Revenue Market Share by Type (2021-2026)
- Figure 16. Product Picture of Short-interval Injections
- Figure 17. Product Picture of Monthly Injections
- Figure 18. Product Picture of Quarterly Injections
- Figure 19. Global Long-acting PrEP Sales Market Share by Dosing Interval in 2026
- Figure 20. Global Long-acting PrEP Revenue Market Share by Dosing Interval (2021-2026)
- Figure 21. Product Picture of Original Drug
- Figure 22. Product Picture of Generic Drug
- Figure 23. Global Long-acting PrEP Sales Market Share by Drug Properties in 2026
- Figure 24. Global Long-acting PrEP Revenue Market Share by Drug Properties (2021-2026)
- Figure 25. Long-acting PrEP Consumed in Hospital
- Figure 26. Global Long-acting PrEP Market: Hospital (2021-2026) & (K Dose)
- Figure 27. Long-acting PrEP Consumed in Clinic
- Figure 28. Global Long-acting PrEP Market: Clinic (2021-2026) & (K Dose)
- Figure 29. Long-acting PrEP Consumed in Other
- Figure 30. Global Long-acting PrEP Market: Other (2021-2026) & (K Dose)
- Figure 31. Global Long-acting PrEP Sale Market Share by Application (2025)

Figure 32. Global Long-acting PrEP Revenue Market Share by Application in 2026

Figure 33. Long-acting PrEP Sales by Company in 2026 (K Dose)

Figure 34. Global Long-acting PrEP Sales Market Share by Company in 2026

Figure 35. Long-acting PrEP Revenue by Company in 2026 (\$ millions)

Figure 36. Global Long-acting PrEP Revenue Market Share by Company in 2026

Figure 37. Global Long-acting PrEP Sales Market Share by Geographic Region (2021-2026)

Figure 38. Global Long-acting PrEP Revenue Market Share by Geographic Region in 2026

Figure 39. Americas Long-acting PrEP Sales 2021-2026 (K Dose)

Figure 40. Americas Long-acting PrEP Revenue 2021-2026 (\$ millions)

Figure 41. APAC Long-acting PrEP Sales 2021-2026 (K Dose)

Figure 42. APAC Long-acting PrEP Revenue 2021-2026 (\$ millions)

Figure 43. Europe Long-acting PrEP Sales 2021-2026 (K Dose)

Figure 44. Europe Long-acting PrEP Revenue 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Long-acting PrEP Sales 2021-2026 (K Dose)

Figure 46. Middle East & Africa Long-acting PrEP Revenue 2021-2026 (\$ millions)

Figure 47. Americas Long-acting PrEP Sales Market Share by Country in 2026

Figure 48. Americas Long-acting PrEP Revenue Market Share by Country (2021-2026)

Figure 49. Americas Long-acting PrEP Sales Market Share by Type (2021-2026)

Figure 50. Americas Long-acting PrEP Sales Market Share by Application (2021-2026)

Figure 51. United States Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 52. Canada Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 53. Mexico Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 54. Brazil Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 55. APAC Long-acting PrEP Sales Market Share by Region in 2026

Figure 56. APAC Long-acting PrEP Revenue Market Share by Region (2021-2026)

Figure 57. APAC Long-acting PrEP Sales Market Share by Type (2021-2026)

Figure 58. APAC Long-acting PrEP Sales Market Share by Application (2021-2026)

Figure 59. China Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 60. Japan Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 61. South Korea Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 62. Southeast Asia Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 63. India Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 64. Australia Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 65. China Taiwan Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)

Figure 66. Europe Long-acting PrEP Sales Market Share by Country in 2026

Figure 67. Europe Long-acting PrEP Revenue Market Share by Country (2021-2026)

Figure 68. Europe Long-acting PrEP Sales Market Share by Type (2021-2026)

- Figure 69. Europe Long-acting PrEP Sales Market Share by Application (2021-2026)
- Figure 70. Germany Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 71. France Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 72. UK Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 73. Italy Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 74. Russia Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 75. Middle East & Africa Long-acting PrEP Sales Market Share by Country (2021-2026)
- Figure 76. Middle East & Africa Long-acting PrEP Sales Market Share by Type (2021-2026)
- Figure 77. Middle East & Africa Long-acting PrEP Sales Market Share by Application (2021-2026)
- Figure 78. Egypt Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 79. South Africa Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 80. Israel Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 81. Turkey Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 82. GCC Countries Long-acting PrEP Revenue Growth 2021-2026 (\$ millions)
- Figure 83. Manufacturing Cost Structure Analysis of Long-acting PrEP in 2026
- Figure 84. Manufacturing Process Analysis of Long-acting PrEP
- Figure 85. Industry Chain Structure of Long-acting PrEP
- Figure 86. Channels of Distribution
- Figure 87. Global Long-acting PrEP Sales Market Forecast by Region (2027-2032)
- Figure 88. Global Long-acting PrEP Revenue Market Share Forecast by Region (2027-2032)
- Figure 89. Global Long-acting PrEP Sales Market Share Forecast by Type (2027-2032)
- Figure 90. Global Long-acting PrEP Revenue Market Share Forecast by Type (2027-2032)
- Figure 91. Global Long-acting PrEP Sales Market Share Forecast by Application (2027-2032)
- Figure 92. Global Long-acting PrEP Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Long-acting PrEP Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/L5110371D72BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L5110371D72BEN.html>